EC2 Software NMIS BioDose: Use of Client-Side Authentication
CVE-2025-61940 is a high-severity use of client-side authentication vulnerability in EC2 Software NMIS BioDose from Mirion Medical, with a CVSS 3.1 base score of 8.8 out of 10. It can be exploited remotely over the network by an attacker with a low-privileged account, without any action from a user. The record lists version 23.0 as the first without the flaw, so updating EC2 Software NMIS BioDose to that release or later removes the exposure. There is no confirmed exploitation so far. EPSS estimates a 0.34% chance of exploitation within 30 days, which is low compared with other CVEs.
High severity with no evidence of exploitation so far.
What to do
- Update EC2 Software NMIS BioDose to 23.0 or a later version.
- Update Biodose/nmis to 23.0 or a later version.
Affected products and versions
| Vendor | Product | Affected versions | Fixed in |
|---|---|---|---|
| Mirion Medical | EC2 Software NMIS BioDose | before 23.0 | 23.0 |
| Mirion | Biodose/nmis | before 23.0 | 23.0 |
Version data comes from the organisation that assigned the CVE. Confirm against the vendor advisory before deciding you are unaffected.
How the severity score breaks down
- Attack vector
- NetworkCan be exploited remotely over a network, including the internet.
- Attack complexity
- LowNo special conditions are needed; the attack works reliably.
- Privileges required
- LowA basic user account is enough.
- User interaction
- NoneNo action by a victim is required.
- Scope
- UnchangedImpact stays within the vulnerable component.
- Confidentiality
- HighAll data handled by the component can be read.
- Integrity
- HighData or code can be modified at will.
- Availability
- HighThe component can be taken down completely.
Vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H. Scored by NVD.
| Scoring system | Score | Severity | Scored by |
|---|---|---|---|
| CVSS 4.0 | 8.7 | High | CNA (hq.dhs.gov) |
| CVSS 3.1 | 8.3 | High | CNA (hq.dhs.gov) |
| CVSS 3.1 | 8.8 | High | NVD |
Official description
NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.
Source: the CVE record as published by its numbering authority, via NVD and CVE.org.
The underlying weakness: Use of Client-Side Authentication
A client/server product performs authentication within client code but not in server code, allowing server-side authentication to be bypassed via a modified client that omits the authentication check.
How developers prevent this class of flaw
- Do not rely on client side data. Always perform server side authentication.
More Use of Client-Side Authentication vulnerabilities (CWE-603)
Timeline
- CVE record published.
- CISA published its SSVC assessment (exploitation: none, automatable: no, technical impact: total).
- Record last changed materially (score, affected products, status or references).
References
Third-party and government advisories
- cisa.gov/news-events/ics-medical-advisories/icsma-25-336-01Third Party Advisory
Other vulnerabilities in EC2 Software NMIS BioDose
- 7.8 High severity
- 7.8 High severity
- 7.5 High severity
- 8.8 High severity
Recent Use of Client-Side Authentication vulnerabilities
- 9.8 Critical severity
- 9.9 Critical severity
- 7.5 High severity
- 7.5 High severity
Spotted an error? Tell us.